Wednesday, May 15, 2019

ImmunoGen's Mirvetuximab isn't dead yet

The Phase III trial of Immunogens Mirvetuximab failed to meet its primary endpoints.  However, that does not mean complete and total death.  It looks like they are continuing to discuss with the FDA and another clinical trial is going to be in the works.

ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer

Hopefully the completion of this trial will lead to success for them, and for the market as a whole.

No comments:

Post a Comment